rs74315369
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_003000.3(SDHB):c.79C>T(p.Arg27Ter) variant causes a stop gained change. The variant allele was found at a frequency of 0.00000186 in 1,613,380 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.0000066 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0000014 ( 0 hom. )
Consequence
SDHB
NM_003000.3 stop_gained
NM_003000.3 stop_gained
Scores
2
4
1
Clinical Significance
Conservation
PhyloP100: 5.92
Genes affected
SDHB (HGNC:10681): (succinate dehydrogenase complex iron sulfur subunit B) This tumor suppressor gene encodes the iron-sulfur protein subunit of the succinate dehydrogenase (SDH) enzyme complex which plays a critical role in mitochondria. The SDH enzyme complex is composed of four nuclear-encoded subunits. This enzyme complex converts succinate to fumarate which releases electrons as part of the citric acid cycle, and the enzyme complex additionally provides an attachment site for released electrons to be transferred to the oxidative phosphorylation pathway. The SDH enzyme complex plays a role in oxygen-related gene regulation through its conversion of succinate, which is an oxygen sensor that stabilizes the hypoxia-inducible factor 1 (HIF1) transcription factor. Sporadic and familial mutations in this gene result in paragangliomas, pheochromocytoma, and gastrointestinal stromal tumors, supporting a link between mitochondrial dysfunction and tumorigenesis. Mutations in this gene are also implicated in nuclear type 4 mitochondrial complex II deficiency. [provided by RefSeq, Jun 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant located near the start codon (<100nt), not predicted to undergo nonsense mediated mRNA decay. There are 122 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 1-17044882-G-A is Pathogenic according to our data. Variant chr1-17044882-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 12783.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr1-17044882-G-A is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SDHB | NM_003000.3 | c.79C>T | p.Arg27Ter | stop_gained | 2/8 | ENST00000375499.8 | NP_002991.2 | |
SDHB | NM_001407361.1 | c.79C>T | p.Arg27Ter | stop_gained | 2/8 | NP_001394290.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SDHB | ENST00000375499.8 | c.79C>T | p.Arg27Ter | stop_gained | 2/8 | 1 | NM_003000.3 | ENSP00000364649 | P1 |
Frequencies
GnomAD3 genomes AF: 0.00000658 AC: 1AN: 151998Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
1
AN:
151998
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000798 AC: 2AN: 250516Hom.: 0 AF XY: 0.00000738 AC XY: 1AN XY: 135486
GnomAD3 exomes
AF:
AC:
2
AN:
250516
Hom.:
AF XY:
AC XY:
1
AN XY:
135486
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461382Hom.: 0 Cov.: 32 AF XY: 0.00000138 AC XY: 1AN XY: 727022
GnomAD4 exome
AF:
AC:
2
AN:
1461382
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
727022
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00000658 AC: 1AN: 151998Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74240
GnomAD4 genome
AF:
AC:
1
AN:
151998
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
74240
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ExAC
AF:
AC:
1
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Paragangliomas 4 Pathogenic:4
Pathogenic, no assertion criteria provided | literature only | OMIM | May 09, 2002 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Human Genome Sequencing Center Clinical Lab, Baylor College of Medicine | Feb 06, 2018 | This c.79C>T (p.R27*) variant is predicted to result in a premature stop codon and has been reported in individuals with pheochromocytoma, paraganglioma and early-onset renal cell cancer (PMID: 12000816, 25215250, 18382370, 14685938, 14685938). In addition, in vitro studies have shown that the c.79C>T (p.R27*) variant alters SDHB expression and function. Therefore we classify this variant as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Feb 08, 2024 | This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. - |
Pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Sep 27, 2021 | ACMG classification criteria: PVS1 very strong, PS3 supporting, PS4 strong, PM2 moderate - |
Hereditary pheochromocytoma-paraganglioma Pathogenic:2
Pathogenic, no assertion criteria provided | research | Section on Medical Neuroendocrinolgy, National Institutes of Health | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 19, 2023 | Variant summary: SDHB c.79C>T (p.Arg27X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Variants downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 8e-06 in 250516 control chromosomes. c.79C>T has been reported in the literature in related individuals affected with Cardiac Paraganglioma, Renal cancer and Lung cancer (Example: Vanharanta_2004). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication have been ascertained in the context of this evaluation (PMID: 14685938). Five submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pheochromocytoma;C0238198:Gastrointestinal stromal tumor;C1861848:Paragangliomas 4 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 26, 2023 | This variant is also known as C213T. For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 12783). This premature translational stop signal has been observed in individual(s) with pheochromocytoma (PMID: 12000816, 12362046, 14685938, 18382370, 19415531, 25215250). This variant is present in population databases (rs74315369, gnomAD 0.005%). This sequence change creates a premature translational stop signal (p.Arg27*) in the SDHB gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SDHB are known to be pathogenic (PMID: 19454582, 19802898). - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 30, 2024 | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Observed in individuals with SDHB-related tumors (PMID: 12362046, 15328326, 18382370, 19415531, 23902947, 25215250, 28374168); Published functional studies demonstrate a damaging effect: absent SDHB protein production, absent SHD enzymatic activity, and abolished association with SDHA (PMID: 25972245); Not observed at significant frequency in large population cohorts (gnomAD); Also known as SDHB 213C>T; This variant is associated with the following publications: (PMID: 31579262, 31666924, 34439168, 29625052, 12000816, 19184535, 26916530, 12362046, 14685938, 15476441, 15328326, 18728280, 17102084, 12213855, 22517557, 25215250, 23902947, 19343621, 19415531, 18382370, 28374168, 30694796, 31492822, 31447099, 30787465, 30201732, 19802898, 27159321, 28784873, 36451132, 25972245) - |
Gastrointestinal stromal tumor Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Aug 13, 2023 | - - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 06, 2023 | The p.R27* pathogenic mutation (also known as c.79C>T), located in coding exon 2 of the SDHB gene, results from a C to T substitution at nucleotide position 79. This changes the amino acid from an arginine to a stop codon within coding exon 2. The predicted stop codon occurs within the first 150 nucleotides of SDHB gene. This alteration may escape nonsense-mediated mRNAdecay and/or be rescued by re-initiation (Rivas et al. Science. 2015 May 8;348(6235):666-9; Lindeboom et al. Nat Genet. 2016 Oct;48(10):1112-8; Rhee et al. Sci Rep. 2017 May 10;7(1):1653), and it impacts the first 57 amino acids of the protein. However, the impacted region is critical for protein function, and a significant portion of the protein is affected (Ambry internal data). This mutation has previously been reported in multiple cases of both sporadic and familial PGL-PCC as well as renal cell carcinoma (Cascón A et al. J. Med. Genet., 2002 Oct;39:E64; Vanharanta S et al. Am. J. Hum. Genet., 2004 Jan;74:153-9; Neumann HP et al. JAMA, 2004 Aug;292:943-51; Naito M et al. Endocrine, 2009 Aug;36:10-5; Graham D et al. Case Rep Genet, 2014 Aug;2014:273423; Casey RT et al. J. Clin. Endocrinol. Metab., 2017 11;102:4013-4022; Fife K et al. BMJ Case Rep, 2017 Aug;2017; Benn DE et al. J. Med. Genet., 2018 11;55:729-734; Albattal S et al. Oncotarget, 2019 Oct;10:5919-5931). Functional studies of this alteration have demonstrated the absence of SDH enzymatic activity as well as the absence of SDHB protein in cell-based assays, indicating nonsense-mediated mRNA decay or protein degradation as a mechanism for absent enzymatic activity (Kim E et al. Endocr. Relat. Cancer, 2015 Jun;22:387-97). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
MutationTaster
Benign
A
Vest4
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at